1-3 of 3
Robert Gharavi, PharmD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Pooled Analysis of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients Treated with the Dual PI3K and HDAC Inhibitor Fimepinostat (CUDC-907), Including Patients with MYC-Altered Disease

Daniel J. Landsburg, MD, Radhakrishnan Ramchandren, MD, Petronella J Lugtenburg, MD PhD, Kevin R. Kelly, MD PhD, Anas Younes, MD, Robert Gharavi, PharmD, David P. Tuck, MD, Stefan Klaus Barta, MD MRCP, MS
Journal: Blood
Blood (2018) 132 (Supplement 1): 4184.
https://doi.org/10.1182/blood-2018-99-112527
Published: 2018
Journal Articles

Objective Responses Achieved in Patients with MYC-Altered Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with the Dual PI3K and HDAC Inhibitor CUDC-907

Daniel J. Landsburg, MD, Rod Ramchandren, MD, Yasuhiro Oki, MD, John M. Pagel, MD PhD, P.J. Lugtenburg, MD PhD, Robert Gharavi, PharmD, Anna Ma, MS, Amir Hafeez, MD, Stefan Klaus Barta, MDMRCP,MS
Journal: Blood
Blood (2017) 130 (Supplement 1): 1555.
https://doi.org/10.1182/blood.V130.Suppl_1.1555.1555
Published: 2017
Journal Articles

Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients with MYC Alterations

Daniel J. Landsburg, MD, Radhakrishnan Ramchandren, MD, Amir Hafeez, MD, Robert Gharavi, PharmD, Tania Chander, PharmD, Anna Ma, MS, Micah M. Burch, MD, Yasuhiro Oki, MD
Journal: Blood
Blood (2016) 128 (22): 5422.
https://doi.org/10.1182/blood.V128.22.5422.5422
Published: 2016